| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3273 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3040 | 2017 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 835 | 2018 |
| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ... Nature medicine 25 (12), 1928-1937, 2019 | 573 | 2019 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 534 | 2018 |
| Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018 | 388 | 2018 |
| Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ... Cancer discovery 7 (3), 277-287, 2017 | 357 | 2017 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 335 | 2022 |
| Accelerating discovery of functional mutant alleles in cancer MT Chang, TS Bhattarai, AM Schram, CM Bielski, MTA Donoghue, ... Cancer discovery 8 (2), 174-183, 2018 | 327 | 2018 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 242 | 2019 |
| PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition P Castel, H Ellis, R Bago, E Toska, P Razavi, FJ Carmona, S Kannan, ... Cancer cell 30 (2), 229-242, 2016 | 232 | 2016 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 202 | 2020 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 184 | 2019 |
| Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning C O’connell, P Razavi, M Ghalichi, S Boyle, S Vasan, L Mark, A Caton, ... Journal of Thrombosis and Haemostasis 9 (2), 305-311, 2011 | 176 | 2011 |
| ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ... Nature genetics 52 (2), 198-207, 2020 | 161 | 2020 |
| Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium BT Li, F Janku, B Jung, C Hou, K Madwani, R Alden, P Razavi, ... Annals of Oncology 30 (4), 597-603, 2019 | 143 | 2019 |
| Shift work, chronotype, and melatonin rhythm in nurses P Razavi, EE Devore, A Bajaj, SW Lockley, MG Figueiro, V Ricchiuti, ... Cancer Epidemiology, Biomarkers & Prevention 28 (7), 1177-1186, 2019 | 140 | 2019 |
| KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function K Gala, Q Li, A Sinha, P Razavi, M Dorso, F Sanchez-Vega, YR Chung, ... Oncogene 37 (34), 4692-4710, 2018 | 128 | 2018 |
| Systematic functional characterization of resistance to PI3K inhibition in breast cancer X Le, R Antony, P Razavi, DJ Treacy, F Luo, M Ghandi, P Castel, ... Cancer discovery 6 (10), 1134-1147, 2016 | 127 | 2016 |
| Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors P Razavi, MN Dickler, PD Shah, W Toy, DN Brown, HH Won, BT Li, ... Nature Cancer 1 (4), 382-393, 2020 | 124 | 2020 |
